<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27893666</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>47</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.</ArticleTitle><Pagination><StartPage>e5304</StartPage><MedlinePgn>e5304</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e5304</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000005304</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Direct antiviral agent (DAA) has been the standard of care for patients with hepatitis C virus (HCV) infection. Twelve weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir (PROD) with or without ribavirin has shown to have a sustained virological response at post-treatment 12 weeks (SVR12) rate of &gt;90% in HCV genotype 1 (HCV-1) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We report a HCV-1b patient who received only 25 days of PROD treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patient early terminated treatment due to dengue fever but eventually achieved SVR12. It may attribute to low baseline viral loads and extraordinarily rapid suppression of HCV after treatment day1.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The finding may shed light for possible response-guided-therapy for so-called ultra-super-responders in the DAA era. Whether the dengue virus, the Flaviviridae family as with HCV, enhanced the HCV clearance remains unclear and needs further exploration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chung-Feng</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University Faculty of Internal Medicine, College of Medicine, Center for Infectious Disease and Cancer Research, Lipid Science and Aging Research Center, Kaohsiung Medical University Department of Occupational Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Department of Laboratory Medicine, and Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung Health Management Center, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Tyng-Yuan</ForeName><Initials>TY</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Po-Liang</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Ming-Lung</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000813">Anilides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003521">Cyclopropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047029">Lactams, Macrocyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047028">Macrocyclic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>2302768XJ8</RegistryNumber><NameOfSubstance UI="C586094">ombitasvir</NameOfSubstance></Chemical><Chemical><RegistryNumber>56HH86ZVCT</RegistryNumber><NameOfSubstance UI="D014498">Uracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>CKR7XL41N4</RegistryNumber><NameOfSubstance UI="D015081">2-Naphthylamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>DE54EQW8T1</RegistryNumber><NameOfSubstance UI="C588260">dasabuvir</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OU2YM37K86</RegistryNumber><NameOfSubstance UI="C585405">paritaprevir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015081" MajorTopicYN="N">2-Naphthylamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000813" MajorTopicYN="N">Anilides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003521" MajorTopicYN="N">Cyclopropanes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047029" MajorTopicYN="N">Lactams, Macrocyclic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047028" MajorTopicYN="N">Macrocyclic Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014498" MajorTopicYN="N">Uracil</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27893666</ArticleId><ArticleId IdType="pmc">PMC5134859</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000005304</ArticleId><ArticleId IdType="pii">00005792-201611220-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26111063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2011;106:2112&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">21971536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">24720702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">24428468</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu ML, Chuang WL. New treatments for HCV: perspective from Asia. Clin Liver Dis 2015;5:17&#x2013;21.</Citation></Reference><Reference><Citation>Yu ML, Dai CY, Huang CF, et al. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J Hepatol 2013;60:253&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24096049</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CF, Dai CY, Lee JJ, et al. Hepatitis C viremia interferes serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics. Hepatol Int 2014;8:224&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">26202503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>